Assistant Professor, Medicine, Weill Cornell Medical College
Oncology
Dr. Steven Sugarman, MD
|
|
Give Review
Steven Sugarman practices Oncology. He went to medical school at State University of New York Downstate Medical Center College of Medicine. Steven Sugarman is a published doctor. He has 23 publications published. The most current publication "Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor." Steven Sugarman is registered with Medicare and accepts Medicare payments.
Publications
- Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast Cancer.
- Tamoxifen-DNA adDucts detected in the endometrium of women treated with tamoxifen.
- Liposomes in the treatment of malignancy: a clinical perspective.
- Identification of tamoxifen-DNA adDucts in the endometrium of women treated with tamoxifen.
- Role of adjuvant therapy in surgically resected coloRectal carcinoma.
- Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic coloRectal carcinoma.
- Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenoCarcinoma.
- Phase II trial of docetaxel (Taxotere) in metastatic coloRectal carcinoma.
- Phase I clinical and plasma and Cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
- Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial Tumors.
- Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast Cancer.
- Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic coloRectal carcinoma.
- Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies.
- The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast Cancer.
- A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast Cancer.
- Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast Cancer is not feasi...
- Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast Cancer is feasible.
- A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast Carcinoma.
- Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast Cancer patients.
- HSP90 inhibition is effective in breast Cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast Cancer prog...
- Troponin I and C-reactive protein are commonly detected in patients with breast Cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
- Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
Schools
SUNY Downstate Medical Center College Of Medicine
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
North Shore-Long Island Jewish Health System -
State University of New York Downstate Medical Center College of Medicine
Hospital
-
Memorial Sloan-Kettering Cancer Center
Drug Facts
| NPI NUMBER | 1073593406 | |
| NPPES Provider LastName | SUGARMAN | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 117255404 | |
| NPPES Provider State | NY | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 720.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 23.0 | |
| Percent Opioid Claims | 3.19 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1073593406 |
| Last Name Of The Provider | SUGARMAN |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
Dr. Jahan Aghalar, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Philip Schulman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John J. Fiore, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Stuart Lichtman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|